Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 232 of 6351
-
Hidden heart risk in obesity: can early screening save lives?
Diagnosis OngoingRationale: Obesity prevalence in Dutch adults increased to 14.2% in 2020. Obesity is strongly associated with cardiovascular disease, especially heart failure (HF). HF is a serious condition with significant morbidity and mortality. HF in people with obesity often remains undete…
Sponsor: Franciscus Gasthuis • Aim: Diagnosis
Last updated Sep 05, 2026 00:00 UTC
-
A new Catheter-Based valve could fix a leaky heart valve without surgery
Disease control Recruiting nowThe objective of the study is to assess the safety and technical feasibility of the Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System
Sponsor: Laplace Interventional, Inc • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Could a nerve stimulator in the neck beat severe depression?
Disease control Recruiting nowDepression is a common illness, affecting 17% of the population over the course of a lifetime. A third of depressions relapses and progresses to recurrence and resistance to treatments. Despite the optimization of antidepressant medical strategies, 20 to 40% of depressions do not…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Transplant patients get new hope: sirolimus cream may stop facial cancers
Disease control Ongoing01.21 SiroSkin is a phase 3, double-blind, multi-centre, parallel-arm, randomised, placebo-controlled trial to evaluate the use of topical 1% sirolimus in the chemoprevention of skin cancer, versus placebo, applied every night for 24 weeks in solid organ transplant recipients.
Phase 3 • Sponsor: Melanoma and Skin Cancer Trials Limited • Aim: Disease control
Last updated Jun 26, 2026 15:07 UTC
-
New shot shows promise against tough blood cancer
Disease control Recruiting nowThe purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have rec…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can an ancient herbal tonic boost modern immunotherapy against lung cancer?
Disease control CompletedThis is a multicenter, open-label, randomized controlled clinical trial designed to evaluate the efficacy and safety of combination therapy with Bojungikki-tang(BJIKT) and pembrolizumab monotherapy in patients with advanced non-small cell lung cancer whose tumors express PD-L1 po…
Phase 2 • Sponsor: Korea Institute of Oriental Medicine • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Skin, speech, and brain scans may unmask hidden neurodegeneration
Diagnosis OngoingThis project will test the hypotheses that people with 5-HT RBD have systemic alpha- synuclein pathology, prodromal DLB signs, and brainstem lesions in regions that control REM sleep. AIM 1 will seek to detect abnormally phosphorylated alpha- synuclein aggregates on targeted skin…
Sponsor: University of Minnesota • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
New pill shows promise for rare childhood diseases
Disease control Recruiting nowThe purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be better than current treatments and with fewer side effects.
Phase 2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 26, 2026 18:37 UTC
-
Barbershops and laundromats become frontline defense against HIV
Prevention Recruiting nowThe purpose of this study is to assess the effectiveness of the FPI bundled implementation strategy in increasing HIV testing, Pre-exposure prophylaxis (PrEP) linkage (e.g., prescription) and knowledge, and condom use/access.
Sponsor: University of Miami • Aim: Prevention
Last updated Aug 30, 2026 00:00 UTC
-
Can a genetic marker make rectal cancer treatment more precise?
Disease control OngoingThis single-arm trial will explore the efficacy and safety of long-course neoadjuvant chemoradiation with liposomal irinotecan and capecitabine guided by UGT1A1 status in patients with locally advanced rectal cancer.
Phase 2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Smartwatch vs. implant: a Non-Invasive way to catch hidden heart rhythm problems?
Diagnosis CancelledNew-onset of atrial fibrillation (AF) and atrial arrythmia (AA) in general, is important as it exposes patients to stroke or other embolic complications not to mention the risk of heart failure. AF detection in high risk populations such as patients with a recent stroke or TIA or…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Aug 27, 2026 00:00 UTC
-
Can a diabetes drug keep the heart in rhythm?
Disease control Recruiting nowSGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomized controlled trial evaluates whether an …
Phase 4 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a diabetes drug and nasal insulin boost brain health?
Disease control Recruiting nowThe investigators propose a proof of concept RCT (randomized clinical trial), testing the efficacy of intranasal insulin (INI) with semaglutide, a combination therapy with strong biological plausibility to benefit impaired cognition through vascular mechanisms, in older adults wi…
Phase 2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New drug combo aims to shrink Hard-to-Treat lung and throat cancers
Disease control Recruiting nowPhase II: To explore the efficacy, safety and tolerability of BL-B01D1+SI-B003 in patients with locally advanced or metastatic non-small cell lung cancer and nasopharyngeal carcinoma, and to further explore the optimal dose and mode of combination.
Phase 2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New study tests if adding a Clot-Buster before mechanical stroke treatment boosts recovery
Disease control CompletedThe purpose of this study is to investigate the safety and efficacy of endovascular treatment with or without preceding intravenous Tenecteplase in patients with late-window (4.5-24 hours of symptom onset) acute ischemic stroke due to middle cerebral artery (MCA) M1 or proximal M…
Phase 3 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
One-and-Done gene shot could spare wet AMD patients from monthly eye needles
Disease control OngoingThe goal of this study is to evaluate the overall safety and efficacy of LX102 gene therapy for nAMD.
Phase 2 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Can a targeted infusion slow muscle decline in duchenne? a new trial aims to find out.
Disease control OngoingAOC 1044-CS2 (EXPLORE44-OLE) is an Open-label Study to Evaluate the Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants with Mutations Amenable to Exon 44 Skipping.
Phase 2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a targeted drug help patients with polymyalgia rheumatica stop steroids faster?
Disease control CompletedThis will be efficacy and safety of Induction and Tapering Therapy with Tofacitinib and Glucocorticoid in patients with Polymyalgia Rheumatica (ITTG PMR): An open-label 52-week randomized controlled trial
Phase 3 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug shot shows promise for tough eczema in large trial
Disease control CompletedThis is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe atopic dermatitis (AD) with a history of inadequate response of topical treatment, on backgroun…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug cocktail aims to extend life in Tough-to-Treat head and neck cancer
Disease control Recruiting nowThe purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuxima…
Phase 3 • Sponsor: AVEO Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC